Terns Pharmaceuticals, Inc.

NasdaqGS:TERN Rapport sur les actions

Capitalisation boursière : US$578.5m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Terns Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Amy Burroughs

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralless than a year
Propriété du PDGn/a
Durée moyenne d'occupation des postes de directionless than a year
Durée moyenne du mandat des membres du conseil d'administration3.7yrs

Mises à jour récentes de la gestion

Recent updates

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Aug 18
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

May 03
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Jan 12
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Sep 29
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Jun 06
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Feb 21
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14
Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

PDG

Amy Burroughs (54 yo)

less than a year

Titularisation

Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Mark Vignola
CFO & Treasurer4yrsUS$3.14m0.033%
$ 190.6k
Seokho Yoon
COO, General Counsel & Secretary3.8yrsUS$3.08m0.033%
$ 190.6k
Amy Burroughs
CEO & Directorless than a yearpas de donnéespas de données
Elona Kogan
Chief Legal Officerless than a yearpas de donnéespas de données
Jeffrey Jasper
Senior VP & Head of Research2.6yrspas de donnéespas de données
Emil Kuriakose
Chief Medical Officer1.3yrspas de donnéespas de données
Melita Jung
Chief Business Officerless than a yearpas de donnéespas de données
Scott Harris
Chief Development Officerless than a yearpas de donnéespas de données

0.9yrs

Durée moyenne de l'emploi

46.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de TERN n'est pas considérée comme expérimentée (ancienneté moyenne 0.9 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Amy Burroughs
CEO & Directorless than a yearpas de donnéespas de données
Carl Gordon
Independent Director5.8yrsUS$298.99k0%
$ 0
Jeffrey Kindler
Independent Director3.7yrsUS$304.99k0%
$ 0
Hongbo Lu
Independent Director4.3yrsUS$299.99k0%
$ 0
Joe Shih
Member of Scientific Advisorno datapas de donnéespas de données
David Fellows
Independent Chairman3.7yrsUS$340.15k0%
$ 0
Stephen A. Harrison
Member of Scientific Advisorno datapas de donnéespas de données
Juan Lopez-Telavera
Member of Scientific Advisorno datapas de donnéespas de données
Radhika Tripuraneni
Independent Director2.1yrsUS$303.06k0%
$ 0
Michael Charlton
Member of Scientific Advisorno datapas de donnéespas de données
Jill Quigley
Independent Director3.7yrsUS$480.49k0%
$ 0
Ann Taylor
Independent Director2.9yrsUS$302.49k0%
$ 0

3.7yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TERN sont considérés comme expérimentés (ancienneté moyenne 3.7 ans).